Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates.
The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries.
Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 25 | -0.10 Decreased by -3.23 K% | -0.07 Decreased by -33.33% |
| Nov 6, 24 | -0.10 Decreased by -25.00% | -0.06 Decreased by -66.67% |
| Aug 8, 24 | -0.04 Increased by +33.33% | -0.05 Increased by +20.00% |
| May 9, 24 | -0.09 Increased by +35.71% | -0.08 Decreased by -12.50% |
| Mar 14, 24 | 0.00 Increased by +108.00% | -0.04 Increased by +108.00% |
| Nov 8, 23 | -0.08 Increased by +71.43% | -0.08 |
| Aug 25, 23 | -0.06 Decreased by -126.09% | -0.02 Decreased by -200.00% |
| May 8, 23 | -0.14 Increased by +60.00% | -0.15 Increased by +6.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 46.50 M Decreased by -17.26% | -22.80 M Decreased by -3.81 K% | Decreased by -49.04% Decreased by -4.59 K% |
| Sep 30, 24 | 37.43 M Decreased by -10.98% | -20.04 M Decreased by -38.30% | Decreased by -53.54% Decreased by -55.37% |
| Jun 30, 24 | 43.65 M Decreased by -22.58% | -8.58 M Increased by +23.18% | Decreased by -19.66% Increased by +0.78% |
| Mar 31, 24 | 32.61 M Decreased by -18.74% | -17.98 M Decreased by -7.45% | Decreased by -55.16% Decreased by -32.23% |
| Dec 31, 23 | 56.20 M Increased by +1.84% | 614.00 K Increased by +107.01% | Increased by +1.09% Increased by +106.89% |
| Sep 30, 23 | 42.05 M Decreased by -14.13% | -14.49 M Increased by +74.00% | Decreased by -34.46% Increased by +69.73% |
| Jun 30, 23 | 56.38 M Decreased by -55.53% | -11.17 M Decreased by -138.16% | Decreased by -19.82% Decreased by -185.80% |
| Mar 31, 23 | 40.13 M Decreased by -34.96% | -16.74 M Increased by +74.77% | Decreased by -41.71% Increased by +61.21% |